Dr. Saro Kasparian, MD

Dr. Kasparian practices at Los Angeles Cancer Network in Glendale, California.

Dr. Kasparian's NPI, 1104350917, was assigned on April 18, 2017. Dr. Kasparian graduated from American University of the Caribbean School of Medicine in 2017. Dr. Kasparian's California license number on file is A166690.

Dr. Kasparian's primary practice is Los Angeles Cancer Network, at 541 W Colorado St, Glendale, CA 91204 in Los Angeles County. The practice phone is (213) 977-1214.

Dr. Kasparian's primary practice is Los Angeles Cancer Network in Glendale, California. Dr. Kasparian is also affiliated with Adventist Health Glendale. The medical group on file is Los Angeles Cancer Network. Dmand AI also links Dr. Kasparian to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kasparian practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kasparian's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kasparian is board certified in hematology by the American Board of Internal Medicine. Dr. Kasparian has a license on file in California.

Dmand AI lists chronic anemia, chronic embolism thrombosis, neutropenia and purpura and thrombocytopenia among the conditions Dr. Kasparian treats.

CMS data shows 15,313 Medicare services from Dr. Kasparian across 28 procedure codes in 2024, for 621 Medicare patients. Medicare paid $453,372 for them.

CMS counts 621 Medicare patients who saw Dr. Kasparian in 2024. The largest group is 65 to 74, with 248 patients. 75% of them have arthritis, and 75% have high blood pressure. 75% are also on Medicaid. Their average risk score is 2.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kasparian's median patient age at 65, with 61% women.

In 2024, Dr. Kasparian wrote 673 Medicare Part D claims for 133 patients. 68% of them were for generic drugs. CMS names the drug for 302 of them, across 16 drugs with 11 or more claims each, at $506,250 in total drug cost. In 2020, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Kasparian for performance year 2024, reported as part of a group. Dr. Kasparian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kasparian as offering telehealth.

Dmand AI links 17 papers to Dr. Kasparian, published from 2014 to 2024. 2019 was the busiest year, with 5. The most frequent topics are 5-Methylcytosine, Cell-Free Nucleic Acids and Lung Neoplasms. Dr. Kasparian has published most often in Cells. Dr. Kasparian's most frequent co-authors are Ethan Alexander Burns, MD, Eric H. Bernicker, MD and Sai Ravi Kiran R. Pingali, MD.

CMS Open Payments shows 556 general payments to Dr. Kasparian from 66 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 94% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,289.

Dr. Kasparian graduated from American University of the Caribbean School of Medicine in 2017. Dr. Kasparian is a member of ASCO.

Dr. Kasparian is in network with 12 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Humana. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.